Is Codeine Stronger Than Oxycodone?

Oxycodone is considerably stronger than codeine on a milligram-for-milligram basis. In pharmacology, oxycodone binds to the brain’s primary opioid receptor roughly ten to a hundred times more tightly than codeine does, which is why doctors classify oxycodone as a “strong” opioid and codeine as a “weak” or “mild” one. But the story gets more interesting when you look at what actually happens in clinical practice, where the gap in pain relief between the two drugs is sometimes surprisingly narrow.

How the Two Drugs Compare at the Receptor Level

Both codeine and oxycodone relieve pain by activating the mu-opioid receptor in the brain and spinal cord, but they do so with very different efficiency. When researchers measure how tightly a drug grabs onto that receptor (a value called the binding constant), codeine falls into the weakest category, with a binding constant above 100 nanomolar. Oxycodone sits in the moderate-strength group, with a binding constant between 1 and 100 nanomolar, alongside drugs like morphine, methadone, and fentanyl.¹ In practical terms, this means oxycodone latches onto its target far more readily than codeine, and that translates to greater pain-relieving potency per dose.

This difference in receptor affinity is a big part of why prescribing guidelines treat the two drugs so differently. A typical codeine dose for moderate pain is 30 to 60 milligrams, while oxycodone achieves comparable or greater relief at 5 to 10 milligrams. That ratio alone tells you oxycodone packs more punch per pill.

Codeine Doesn’t Really Work Until Your Liver Converts It

One of the most important things to understand about codeine is that it’s essentially a prodrug. On its own, codeine does very little at the opioid receptor. Your liver has to convert it into morphine before it provides meaningful pain relief, and that conversion is handled by a specific enzyme called CYP2D6.² Only a fraction of each codeine dose actually becomes morphine; the rest is processed into other metabolites that contribute much less to pain control.

Oxycodone, by contrast, is active on its own. It doesn’t need to be converted into another molecule to relieve pain. Your liver does break it down into several metabolites, including oxymorphone, which is itself a potent opioid, but oxycodone’s pain relief doesn’t depend on that conversion step. This fundamental difference means that codeine’s effectiveness is more variable from person to person, while oxycodone tends to deliver a more predictable response.

Your Genes Decide How Well Codeine Works for You

Because codeine relies on CYP2D6 to become active, genetic differences in that enzyme can dramatically change the drug’s effect. The gene encoding CYP2D6 is one of the most variable in the human genome. Roughly 5 to 10 percent of people of European descent are “poor metabolizers” who produce little or no functional CYP2D6. For these individuals, codeine barely works at all because almost none of it gets converted to morphine.³

At the other extreme, some people carry extra copies of the CYP2D6 gene, making them “ultra-rapid metabolizers.” A study of these individuals found that after a single 30-milligram dose of codeine, ultra-rapid metabolizers had about 50 percent higher blood levels of morphine compared to people with normal metabolism. Over 90 percent of the ultra-rapid group reported sedation, compared with half of the normal metabolizers.⁴ For these people, a standard codeine dose can produce dangerously high morphine levels, leading to excessive sedation and respiratory depression.

This genetic lottery doesn’t affect oxycodone in nearly the same way. While CYP2D6 does play a minor role in oxycodone metabolism, oxycodone’s pain relief doesn’t hinge on that enzyme. So someone who gets no benefit from codeine may respond perfectly well to oxycodone, and someone who experiences dangerous toxicity from codeine may handle oxycodone without incident. This unpredictability is one of the strongest arguments against treating the two drugs as interchangeable.

Clinical Trials Tell a Surprisingly Close Story

Given the wide gap in potency at the receptor, you might expect oxycodone to crush codeine in head-to-head pain trials. The reality is more nuanced. When both drugs are paired with acetaminophen (as they commonly are in real-world prescribing), the difference in pain relief often shrinks to the point of being clinically meaningless.

A randomized trial comparing oxycodone/acetaminophen to codeine/acetaminophen in emergency department patients with acute pain found that pain scores dropped by about 4.5 points in the oxycodone group and 4.2 points in the codeine group over two hours. That 0.2-point difference was neither clinically nor statistically significant. About two-thirds of patients in both groups achieved more than a 50 percent reduction in pain, and side-effect profiles were similar.⁵

A separate randomized trial looking at patients recovering from surgically treated fractures found a similar pattern. Patients given oxycodone reported average daily pain scores of about 4.0, while those given codeine/acetaminophen reported scores of about 4.5. That half-point gap was not statistically significant, even though the oxycodone group received roughly six times the opioid dose in morphine-equivalent terms.⁶ That finding is worth sitting with: a sixfold increase in opioid exposure did not translate into meaningfully better pain control.

These results don’t mean the drugs are equally powerful. They suggest that for many common acute pain scenarios, codeine combined with acetaminophen reaches a level of relief that oxycodone doesn’t dramatically improve upon. The acetaminophen is doing a lot of the heavy lifting, and once pain is being adequately managed, piling on more opioid potency hits diminishing returns.

Side Effects and How They Differ

Both drugs produce the classic opioid side effects: nausea, constipation, drowsiness, and dizziness. In cancer pain studies, codeine’s reported side-effect rates included about 36 percent for nausea, 30 percent for constipation, and 22 percent for sleepiness.⁷ Oxycodone tends to produce similar side effects but often at higher rates in direct comparisons. A trial comparing the two after wisdom tooth extraction found that drowsiness, dizziness, and headache were reported more frequently in the oxycodone group.⁸

Codeine has one side effect that stands out: it causes histamine release at higher rates than most other opioids. This means more itching, flushing, and occasionally mild allergic-type reactions. Oxycodone releases less histamine, which is part of why it’s sometimes better tolerated in patients who react badly to codeine’s non-opioid effects. That said, both drugs can cause all the usual opioid problems, including the constipation that plagues nearly every opioid user regardless of which specific drug is prescribed.

Overdose Risk Is Substantially Different

When it comes to the most dangerous consequence of opioid use, severe respiratory depression during overdose, the two drugs are in different leagues. A study examining risk factors for severe respiratory depression found that codeine had one of the lowest rates of severe respiratory depression among opioid overdoses at about 3.6 percent.⁹ This low rate likely reflects codeine’s dependence on the metabolic conversion step, which acts as a built-in ceiling. Even in overdose, most people can only convert so much codeine into morphine, so the body’s capacity to produce the truly dangerous metabolite is limited. Ultra-rapid metabolizers are the exception, but they represent a small fraction of the population.

Oxycodone, being active on its own, doesn’t have that metabolic bottleneck. Its respiratory depression risk scales more linearly with dose. This is one of the clearest safety distinctions between the two, and it partly explains why some countries have historically allowed low-dose codeine products to be sold over the counter while keeping oxycodone under tight prescription controls.

Kidney Disease Changes the Calculation

For people with impaired kidney function, the comparison between these two drugs shifts in ways that may surprise you. Both become more dangerous in kidney disease, but codeine is generally considered the worse option. Reviews of opioid use in renal failure recommend that codeine be avoided entirely in dialysis patients, while oxycodone can be used with caution and dose reduction.¹⁰

The reason comes back to codeine’s conversion to morphine. Morphine’s metabolites are cleared by the kidneys, and when the kidneys aren’t working well, those metabolites build up and can cause serious toxicity including confusion, extreme sedation, and respiratory failure.¹¹ Oxycodone’s metabolites also accumulate in kidney disease, with peak blood levels rising roughly 50 percent above normal, and the drug takes longer to leave the body.¹² But oxycodone can be managed with careful dose adjustments, whereas codeine’s unpredictable conversion to morphine makes it harder to control safely in this population.

Why Scheduling and Legal Status Don’t Reflect Potency Alone

In many countries, codeine and oxycodone sit at different levels of regulatory control. In the United States, oxycodone is a Schedule II controlled substance (the most tightly restricted category for drugs with accepted medical use), while codeine can be Schedule II, III, or V depending on the formulation and dose. Low-dose codeine combined with other ingredients often falls under lighter restrictions.

Australia provides an instructive case study in how regulatory changes can reshape prescribing. When Australia up-scheduled codeine from over-the-counter to prescription-only in February 2018, dental prescriptions for opioids shifted. In the year following the change, prescriptions for codeine/paracetamol combinations rose by about 21 percent, and oxycodone prescriptions increased by roughly 24 percent.¹³ The policy that was meant to reduce opioid access appears to have pushed some patients toward stronger prescriptions, illustrating how regulatory decisions can have unintended consequences in the opioid landscape.

Breastfeeding and Codeine’s Unique Danger

For nursing mothers, codeine carries a specific risk that oxycodone doesn’t share in the same way. Because codeine’s conversion to morphine depends on CYP2D6, an ultra-rapid metabolizer who takes codeine can produce high levels of morphine that pass into breast milk. This has led to documented cases of infant sedation and, in rare instances, fatal outcomes. The unpredictability of who carries ultra-rapid metabolism genes makes this risk hard to manage without genetic testing.

That said, researchers have noted that oxycodone also passes into breast milk and that individual variation in how mothers process oxycodone creates its own uncertainties. One review emphasized that simply replacing codeine with another opioid doesn’t eliminate the pharmacokinetic unpredictability in breast milk exposure.¹⁴ The safest approach for any opioid during breastfeeding remains using the lowest effective dose for the shortest possible time, with close monitoring of the infant for drowsiness or poor feeding.

Longer-Term Use and Depression Risk

An underappreciated difference between these drugs emerged from a large pharmacoepidemiologic study examining new depression diagnoses among opioid users. Patients who took codeine for 30 days or longer had a 29 percent higher risk of receiving a new depression diagnosis compared to those prescribed hydrocodone over the same period. Oxycodone users did not show a significantly elevated risk compared to hydrocodone users.¹⁵ This is a single observational study and shouldn’t be over-interpreted, but it adds another dimension to the comparison that goes beyond simple pain scores. The mechanisms behind this association aren’t well understood, and confounding factors could play a role, but it’s a finding worth flagging for anyone weighing longer courses of either drug.

The broader point is that “stronger” is a more complicated label than it first appears. Oxycodone is unquestionably more potent at the receptor, commands more regulatory caution, and carries higher overdose risk per dose. Yet in the clinical contexts where most people actually encounter these drugs, the difference in pain relief can be surprisingly small, the side-effect profiles overlap heavily, and the choice between them often comes down to individual factors like genetics, kidney function, and what other medications someone is taking rather than raw potency alone.